Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb 15;3(2):100532.
doi: 10.1016/j.xcrm.2022.100532.

The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery

David B Page  1
Affiliations
Comment

The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery

David B Page. Cell Rep Med. .

Abstract

The Human Tumor Atlas Network is a multi-institutional effort to generate genomic and histologic datasets spanning thousands of patients. Johnson et al., in this issue of Cell Reports Medicine, illustrate how disparate data types from a single case can be combined to discover novel therapeutic directions.

PubMed Disclaimer

Conflict of interest statement

D.B.P. holds a compensated advisory position for Brooklyn ImmunoTherapeutics, Genentech, Merck Sharpe & Dohme, Puma, Sanofi, Biotheranostics, Lilly. D.B.P. receives speaker’s bureau honoraria from Genentech and Novartis. DBP receives indirect research support from Merck Sharpe & Dohme, Brooklyn ImmunoTherapeutics, WindMIL, and Bristol Myers Squibb.

Figures

Figure 1
Figure 1
Hypothesized mechanism of tumor outgrowth following capecitabine exposure Combined DNA and RNA transcriptional profiling of serial biopsies (Bx2, Bx3, Bx4) revealed an acquired amplification of a region of chromosome 18 encoding TYMS and YES1. TYMS is the molecular target of capecitabine, and upregulation may confer therapeutic resistance, whereas YES1 is a putatively oncogenic receptor tyrosine kinase. A later biopsy (Bx4) redemonstrated co-amplification, but showed increasing YES1 expression, suggesting a YES1-mediated mechanism of tumor outgrowth.
See this image and copyright information in PMC

Comment on

  • An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer.
    Johnson BE, Creason AL, Stommel JM, Keck JM, Parmar S, Betts CB, Blucher A, Boniface C, Bucher E, Burlingame E, Camp T, Chin K, Eng J, Estabrook J, Feiler HS, Heskett MB, Hu Z, Kolodzie A, Kong BL, Labrie M, Lee J, Leyshock P, Mitri S, Patterson J, Riesterer JL, Sivagnanam S, Somers J, Sudar D, Thibault G, Weeder BR, Zheng C, Nan X, Thompson RF, Heiser LM, Spellman PT, Thomas G, Demir E, Chang YH, Coussens LM, Guimaraes AR, Corless C, Goecks J, Bergan R, Mitri Z, Mills GB, Gray JW. Johnson BE, et al. Cell Rep Med. 2022 Feb 15;3(2):100525. doi: 10.1016/j.xcrm.2022.100525. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35243422 Free PMC article.

References

    1. Johnson B.E., Creason A.L., Stommel J.M., Keck J.M., Parmar S., Betts C.B., Blucher A., Boniface C., Bucher E., Burlingame E., et al. An Omic and Multidimensional Spatial Atlas from Serial Biopsies of an Evolving Metastatic Breast Cancer. Cell Reports Medicine. 2022;3:100525-1–100525-16. - PMC - PubMed
    1. Rozenblatt-Rosen O., Regev A., Oberdoerffer P., Nawy T., Hupalowska A., Rood J.E., Ashenberg O., Cerami E., Coffey R.J., Demir E., et al. Human Tumor Atlas Network The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020;181:236–249. - PMC - PubMed
    1. Takeda T., Yamamoto H., Kanzaki H., Suzawa K., Yoshioka T., Tomida S., Cui X., Murali R., Namba K., Sato H., et al. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE. 2017;12:e0171356. - PMC - PubMed
    1. Garmendia I., Pajares M.J., Hermida-Prado F., Ajona D., Bértolo C., Sainz C., Lavín A., Remírez A.B., Valencia K., Moreno H., et al. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. Am. J. Respir. Crit. Care Med. 2019;200:888–899. - PubMed
    1. Wu L., Saxena S., Goel P., Prajapati D.R., Wang C., Singh R.K. Breast Cancer Cell-Neutrophil Interactions Enhance Neutrophil Survival and Pro-Tumorigenic Activities. Cancers (Basel) 2020;12:2884. - PMC - PubMed